These data indicate that the CD14+CD16−HLA-DRlowCD33dim subcluster was diminished in patients with progressive disease, warranting further investigation of this subpopulation of monocytes in relation to anti-tumor activity. This evidence concerns the gene CD14 and neoplasm.